Can-Fite BioPharma (NYSE:CANF) Receives “Buy” Rating from D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Can-Fite BioPharma (NYSE:CANF) in a research report report published on Tuesday morning,Benzinga reports. The firm currently has a $10.00 price objective on the stock.

Other analysts have also recently issued research reports about the stock. HC Wainwright reiterated a “buy” rating and set a $18.00 price target on shares of Can-Fite BioPharma in a research note on Tuesday, November 12th. StockNews.com started coverage on shares of Can-Fite BioPharma in a research note on Tuesday, February 11th. They set a “sell” rating for the company.

Can-Fite BioPharma Trading Up 2.0 %

Shares of Can-Fite BioPharma stock opened at $1.56 on Tuesday. The company has a fifty day simple moving average of $1.54 and a 200-day simple moving average of $2.00. Can-Fite BioPharma has a 12-month low of $1.29 and a 12-month high of $4.69. The stock has a market cap of $5.52 million, a price-to-earnings ratio of -0.87 and a beta of 1.33.

Institutional Trading of Can-Fite BioPharma

An institutional investor recently bought a new position in Can-Fite BioPharma stock. BNP Paribas Financial Markets bought a new position in Can-Fite BioPharma Ltd. (NYSE:CANF) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 25,185 shares of the company’s stock, valued at approximately $41,000. BNP Paribas Financial Markets owned 0.71% of Can-Fite BioPharma as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 21.00% of the company’s stock.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.